CNP Variants With Hydrolysable Linkers for Bone Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The therapeutic use of C-type natriuretic peptide (CNP) is limited by its short plasma half-life, which hampers its effectiveness in treating bone-related disorders such as achondroplasia due to its rapid degradation in vivo.
Innovation Solution
Development of novel CNP variants with increased circulating half-life and stability in aqueous media, incorporating conjugate moieties and hydrolysable linkers, which are designed to release the peptide slowly over time, maintaining therapeutic activity while extending its duration in the body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CNP is used for therapeutic treatment, then it can treat bone-related disorders, but its short plasma half-life limits its effectiveness
Solution Approach 1:
The patent introduces hydrolysable linkers as intermediary components that connect CNP peptides to extend their circulation time. These linkers act as mediators between the CNP molecule and the body's degradation enzymes, controlling the release rate and thereby extending the effective duration of CNP action in the plasma
Solution Approach 2:
The patent modifies the chemical parameters of CNP by incorporating various hydrolysable linkers with different bond strengths and hydrolysis rates. This changes the degradation kinetics of CNP, transforming it from a rapidly degraded peptide to a sustained-release therapeutic agent with extended plasma half-life
2Reliability
If CNP is administered frequently to maintain therapeutic levels, then therapeutic effect is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
The hydrolysable linkers enable continuous release of active CNP over an extended period, transforming the discontinuous dosing requirement into a continuous therapeutic action. This allows the drug to maintain effective concentrations throughout the dosing interval, eliminating the need for frequent administration
3Duration of action of stationary object
If CNP stability in aqueous media is improved, then therapeutic activity is maintained longer, but molecular structure modifications are required
Solution Approach 1:
The patent segments the CNP molecule by inserting hydrolysable linkers at specific positions within the peptide sequence. This segmentation creates modular units that can be independently optimized for stability while maintaining the overall biological activity of the CNP structure
Solution Approach 2:
The patent creates composite peptide structures by combining CNP sequences with hydrolysable linker moieties. This composite approach integrates the stability-conferring properties of the linker design with the bioactive properties of CNP, achieving enhanced aqueous stability without completely altering the core therapeutic molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CNP variants exhibit a significantly longer half-life, achieving sustained therapeutic effects and improved stability, allowing for more effective treatment of bone-related disorders by maintaining activity over a longer period.
Implementation Method 1
CNP interacts with natriuretic peptide receptor-B (NPR-B, GC-B) to stimulate the generation of cyclic- guanosine monophosphate (cGMP)
Data Source
AI summary
The present disclosure, relates, in general, to stable variants of C-type natriuretic peptide (CNP) and uses thereof to treat bone-related disorders.